1. INTRODUCTION:

An autosomal dominant, uncommon, fatal childhood segmental premature aging disorder is called Hutchinson-Gilford-Child syndrome (HGPS). Jonathan Hutchinson initially identified patients with Hutchinson-Gilford ancestry in 1886. His colleague Hastings Gilford later aged these patients and termed the disorder gene [premature senile] in 1904. The Greek words pro, which means "before" or "premature," and gears, which means "old age," are the sources of the word progenies.^1-5 Lamina A, a mutant form of progeria, is synthesized when a spontaneous point mutation in the low-grade appendicular mucosal neoplasm [LAMN] gene occurs, causing HGPS.

About 140 children in 50 nations have progeria, according to the Progeria Research Foundation database, and 1 in 4 to 8 million live births are thought to have HGPS. Five to ten times quicker than average aging, children with Hutchinson Gilford progeria replicate the pertinent clinical traits observed in older adults. Regretfully, there is no effective treatment or cure to stop or undo the harmful effects of HGPS in aging children.^6-9. Children that experience this throughout their first two years of life age quickly. Progeria babies typically seem healthy when they are born. Symptoms include hair loss, adipose tissue loss, and stunted growth start to show up in the first year. Most children with progenies die from heart problems or stroke in the end. A child with progeria typically has a life expectancy of 15 years. Some patients may live up to 20 years or more ¹⁰. Progeria affects 350-400 children globally, impacting around one in twenty million people. Initially identified in 1886, it was initially unknown. French scientists discovered point mutations in LAMN genes in 2003. Progeria-like conditions, such as hypo-plastic articular eminences and mandibular condyles, can lead to serious atherosclerosis problems. Lonafarnib, a farnesyltransferase inhibitor, was approved in the US in 2020 to treat progeria laminopathy and lower mortality risk.^{11-16, 54-64}

Figure 1: Photographic stages of Progeria year-wise 17

2. ETIOLOGY:

Progeria, truncated prelaminar A, is linked to aberrant processing of the nuclear envelope protein Lamina A and accumulation in cases of HGPS. The majority of HGPS cases are caused by autosomal dominant mutations in the LMNA gene, which is situated in the 1q21.1–1q21.3 areas. Most cases are caused by de novo mutations related to paternal age, however somatic and gonadal mosaicism have also been observed to be associated with asymptomatic maternal transmission of the mutant LMNA gene. Furthermore, it has been proposed that autosomal recessive transmission explains the observed occurrence of HGPS in some siblings born to healthy parents.

Nuclear A-type lamins, or V-type intermediate filament proteins, are encoded by LMNA genes. These proteins localize to the cell nucleus where they create the nuclear membrane, which supports the nuclear envelope. They play a crucial role in keeping nuclear stability and chromatin organization intact. Moreover, nuclear lamin is involved in the control of DNA synthesis, DNA repair, and gene expression. (18, 19, 20) A hereditary condition known as HGPS syndrome causes protective DNA repair systems to stop working. Although genetic instability is a typical aspect of aging, the body cannot fix these anomalies in HGPS syndrome. This causes a build-up of genetic instability, which shows up in the affected person as an early aging phenotype. Only specific tissue types are impacted by premature aging. (21-23).

Table 1: A Comparison between a Progeria Cell with A Normal Cell.

Stages in a normal cell	Steps in the progerian cell
The LAMN gene codes for a protein called prelamin A.	The LAMN gene codes for a protein called prelamin A.
relamin A has a farnesyl group at the end.	Prelamin A has a farnesyl group at the end.
he farnesyl group is removed from preamine A.	The farnesyl group is attached to prelamin A.
he normal form is called prelamin A.	An abnormal form of prelamin a called progeria.
relamin A is not anchored to the nuclear periphery.	Progeria is anchored in the nucleus.
he normal state of the kernel.	Abnormally shaped nucleus.

3. EPIDEMIOLOGY:

One in four to eight million neonates are born with HGPS, a relatively rare genetic disorder. Every ethnicity and gender was equally impacted by HGPS. Progeria is thought to be equally common everywhere, irrespective of gender, geography, or ethnic prejudice. Nowadays, 300–350 progeria-affected children are found simultaneously all over the world. As of right now, 39 countries and about 114 children have been diagnosed with HGPS. Based on the number of instances, progeria is thought to affect one in eight million babies in the United States.^24-27.

3.1 Sex:

HGPS has a male-to-female ratio of 1.5:1, indicating a slight predilection for men.

3.2 Age:

Even though many affected children exhibit scleroderma tic skin abnormalities, clinical signs of HGPS may not be identified or seen at birth. It takes until 6–12 months of age or older to recognize facial characteristics, skin, and musculoskeletal manifestations. At that point, developmental failure necessitates a more complete evaluation.¹⁸

4. PATHOPHYSIOLOGY:

Patients with HGPS experience accelerated aging, including brain and coronary artery atherosclerosis. The only lipid aberration associated with progeria is a reduction in high-density lipoprotein cholesterol. HGPS is considered a segmental progeria syndrome, affecting organs like kidneys, brain, adrenal glands, liver, testicles, and heart. Defects in Lamina A, a protein controlling cellular functions, lead to genomic instability, decreased cell proliferation, and early cell senescence.^18,28,29.

The LMNA gene at codon 608 of exon 11 of chromosome 1 is the site of nearly all de novo point mutations that cause HGPS, a sporadic autosomal dominant disease. Three proteins known as Lamina A (LA), Lamina C (LC), and Lamina 10, a complex molecular interface in the inner nuclear membrane, are encoded by the LMNA gene and make up the nuclear laminae. It is now known that the lamina is crucial for transcription, nuclear structure, DNA replication, chromatin organization, and cell division. A C-T nucleotide substitution that results in a cryptic splice donor site at position 1824 and a change in the encoded amino acids is the typical form of LMNA mutation in HGPS. The mRNA is missing 150 nucleotides when this site is active. After being translated, this mRNA results in progeria, an abnormal protein that has an internal deletion of 50 amino acids close to the C-terminus. ^{11,16,30,31,32,33}.

Figure 2: The HGPS System ^11,34,35,36

It is believed that progeria significantly impair the nuclear function of cells that express LA. It is also believed to hinder other vital functions, including transcription of genes, DNA replication, and cell division^37,38,39. Progeria was found to preferentially accumulate in smooth muscle and vascular endothelial cells. Clinically, progeria-affected children experience substantial sporadic fibrosis, arteriosclerosis of tiny vessels, and increased progeria deposits in the coronary arteries. Peripheral vascular occlusive disease and accelerated vascular stiffening are cardiovascular manifestations of typical aging atherosclerosis.^18,40,41,42.

Figure 3: Main clinical features of progeria syndrome⁴³

Note that the pathophysiology of HGPS is not only the lack of normal Lamina A function but also the presence of progeria and a dominating negative effect on Lamina A function.¹⁸.

5. SYMPTOMS:

· Progeria symptoms manifest at a much younger age, yet they seem like typical human aging. Children with progeria start exhibiting signs and symptoms of fast aging throughout their first two years of life. These symptoms include:

· failure to grow or small stature.

· Skin itching and being bald.

· Restricted range of motion and stiff joints.

· Rough skin akin to scleroderma and decrease in body mass.

Figure 4: Symptoms⁴⁴

Anomalous craniofacial conditions can include:

· A broad, open soft area on the head called a fontanelle.

· Small face compared to the size of the skull (macrocephaly).

· Beak and Teeth (delayed eruption) eruption delayed.

· Micrognathia, or small, undeveloped jaw.

Less Obvious Symptoms May Occur as the Condition progresses. they include:

· Positioning of the Hips, The Cataract, Arthritis and Artery Plaque Accumulation.^44,54

Health problems include e.g.

· enlarged hip and skin thickening and disorders of the heart.

· fragile bones and Loss of muscle mass.

· insulin resistance and delayed tooth development or growth.

· rigidity in the joints and if your child exhibits any of these progeria symptoms, you must consult a specialist to ensure appropriate diagnosis and treatment.

Possible Risks:

· Stroke and Atherosclerosis and Heart attack and Congestive heart failure.^45,54-59

6. DIAGNOSIS:

Your child's doctor will assess insulin resistance, cholesterol, and triglyceride levels by laboratory testing after reviewing your child's medical history and symptoms.

To check for cardiac anomalies, they will also ask for genetic testing and stress testing.

Progeria has no known cure and no particular treatment, however, taking aspirin every day can prevent heart attacks and strokes.

The doctor may prescribe anticoagulants to avoid blood clots, statins to control cholesterol, and drugs to help with blood pressure, migraines, and seizures, depending on your child's symptoms.

To improve your child's quality of life and slow the progression of the disease, they will also recommend a high-calorie diet, physical and occupational therapy sessions, and routine dental and general examinations.⁴⁵

A thorough physical exam of Your Child Includes:

· weighing and measuring the person and measuring and charting a growth curve.

· testing the eyes and ears and taking vital signs measurements, such as blood pressure.

· searching for progeria's outward manifestations.⁴⁶

Hearing aids:

While most low-frequency hearing loss does not interfere with day-to-day activities, there are situations where hearing aids or listening devices are necessary.

Eye and vision care:

Closing the eyelids completely can cause dry eyes and damage to the ocular surface. Moisturizing eye products and regular eye care can help.

Dental care:

Closing the eyelids completely can cause dry eyes and damage to the ocular surface. Moisturizing eye products and regular eye care can help.⁴⁶

Diagnostic Methods:^24,45-52

To diagnose progeria, doctors looked at phenotypes, such as physical symptoms such as skin changes and weight gain, as well as X-rays of patients and tests for glycosaminoglycan excretion and urinary hyaluronic acid, and X-rays.

Imaging Studies:

Diagnosis currently depends on the recognition of clinical and radiographic findings. The clinical diagnosis can also be confirmed by the findings - diastasis of the sagittal suture, skull with several vermiform bones; hypoplastic mandible with infantile angle; the presence of oral vertebrae in fish; the presence of bilateral cake deformities; resorption of the fingertips, etc. Progressive bone loss in the distal parts of the fingers and toes is one of the hallmarks of the disease.

Molecular Diagnostic Test:

Mutation screening is certainly theoretically possible, especially as the cost of genomic DNA analysis decreases. Due to the randomness of the phenotype, predictive screening is not currently performed in practice because it is not possible to determine which children are at risk.

Laboratory studies:

Abnormalities in serum lipid levels, limited to low levels of high-density lipoproteins, predispose to atherosclerotic disease. Serum low-density lipoprotein and total cholesterol levels are normal in (HGPS) patients.

Urinary Hyaluronic Test:

Increased urinary excretion of hyaluronic acid is seen in patients with HGPS but is not diagnostic. The significance in patients with HGPS is unknown, but they are not diagnostic. The meaning is unknown. After urine hyaluronic analysis of a patient with HGPS, the level of hyaluronic acid in the urine increased and the level of primary antioxidant enzymes and some fatty acid compounds in the blood decreased. Since the concentration of antioxidant enzymes in the blood is reduced, this can lead to aging, which is thought to accumulate in the blood as an oxidant. Most patients have an increased content of urinary hyaluronic acid. Oh, HGPS measurement is now considered unreliable and not recommended for diagnosis. The definitive diagnosis report is provided by the discovery of the mutant lamin gene, which today helps to identify the elevated mutant gene identified by the mutant gene from the patient's blood sample and skin biopsy. On the other hand, phenotypic evidence and the anamnesis of the child, this genetic test for lamin mutations is done to confirm the diagnosis of HGPS, so that treatment programs can begin at an early stage of the progression of the disease.

Rental Testing:

In HGPS children, the dead cell DNA analysis using amino races, used for prenatal diagnosis, was mostly performed at about 15-18 years of age or from a chronic bladder sample at about 10-12 years of age. Prenatal testing of affected family members should identify disease-causing alleles. In the case of a preimplantation genetic disorder in the family, this can be available by having the cause of the disease identified in an affected family member.

Other Tests:

EKG and echocardiography are performed to detect coronary artery disease and congestive heart failure.

7. TREATMENT:

Lonafarnib (Zokinvy) is the first drug approved by the US Food and Drug Administration (FDA) for HGPS. Lonafarnib is a farnesyltransferase inhibitor (FTI). It was approved by the FDA in November 2020 for the treatment of HGPS and progeria laminopathies. An international observational study (n = 258) showed that lonafarnib monotherapy was associated with lower mortality compared to no therapy after 2.2 years of follow-up. (18, 53) During medical visits, the weight and height of patients are measured and recorded on a chart showing the average measurements for the child's age. Routine evaluations often include EKGs and echocardiograms to check the heart, imaging tests such as X-rays and MRIs, and dental, vision, and hearing exams. Certain treatments can relieve or delay some of the symptoms of progeria. Treatment depends on the patient's condition and symptoms. These may include:

Low-Dose Aspirin:

A daily dose can help prevent heart attacks and strokes.

Other Medicines:

Depending on your child and your condition, your doctor may prescribe different medications to treat complications. These may include nutritional therapy, possibly statins, to help the blood vessels and heart function. Also, blood thinners to prevent blood clots. Medications may be needed to treat headaches and other symptoms.

Physical and Occupational Therapy:

Physical therapy can help with joint stiffness and hip problems to help your child stay active. Occupational therapy can help a child learn ways to manage daily activities such as dressing, brushing teeth, and eating.⁴⁶

HGPS has no specific treatment, but it is monitored for cardiovascular diseases and atherosclerotic diseases. Physical activity, physiotherapy, and hydrotherapy can help. Supplements like gastrostomy tubes are used for children with poor feeding. Growth hormone and farnesyltransferase inhibitors may help promote gene release from the nuclear membrane, overcoming structural and functional issues.

8. CONCLUSION:

Hutchinson-Gilford syndrome (HGPS) is a rare genetic disorder characterized by segmental accelerated aging and rapid aging shortly after birth. It affects various organ systems, including the central nervous system, and is caused by a point mutation in the LMNA gene. The disease causes symptoms like growth failure, baldness, eyebrow loss, lip dystrophy, scleroderma, decreased joint mobility, and facial features reminiscent of aging. The most common mutation is at codon 608 (G608G), which creates a cryptic splice site in exon 11 that removes the proteolytic cleavage site for the mutant lamin A. There is no effective treatment for HGPS, but it is important to monitor cardiovascular diseases and use low-dose aspirin for cardiovascular atherosclerosis.

9. REFERENCE:

1. Ulrich, N. J., and Gordon, L. B. (2015). Hutchinson–Gilford progeria syndrome. In Handbook of Clinical Neurology (pp. 249–264). https://doi.org/10.1016/b978-0-444-62702-5.00018-4

2. Liu GH, Suzuki K, Qu J, Sancho-Martinez I, Yi F, Li M, Kumar S, Nivet E, Kim J, Soligalla RD, Dubova I, Goebl A, Plongthongkum N, Fung HL, Zhang K, Loring JF, Laurent LC, Izpisua Belmonte JC. Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell. 2011 Jun 3; 8(6):688-94. doi: 10.1016/j.stem.2011.04.019.

3. Liu GH, Ding Z, Belmonte JC. iPSC technology to study human aging and aging-related disorders. Current Opinion in Cell Biology. 2012 Dec 1; 24(6): 765-74.

4. Progeria. Cleveland Clinic. 2024. Available from: https://my.clevelandclinic.org/health/diseases/17850-progeria

5. Progeria - Symptoms and causes - Mayo Clinic. Mayo Clinic. 2023. Available from: https://www.mayoclinic.org/diseases-conditions/progeria/symptoms-causes/syc-20356038

6. Cisneros, B., Garcia‐Aguirre, I., De Iota, M., Arietta‐Cruz, I., and Rosas-Vargas, H. Hutchinson-Gilford Progeria Syndrome: Cellular mechanisms and therapeutic Perspectives. Archives of Medical Research. 2023; 54(5): 102837. https://doi.org/10.1016/j.arcmed.2023.06.002

7. Foo, M. X. R., Ong, P., and Dresden, O. Premature aging syndromes: Frompatient’smechanism. Journal of Dermatological Science. 2019; 96(2): 58–65.

8. The Progeria Research Foundation. For the Children For the Cure. 2024. Available from: https://www.progeriaresearch.org/

9. JK Sinha, S Ghosh, M. Raghunath. Progeria: a rare genetic premature aging disorder Indian J Med Res. 2014; 139: 667-674. Available-from- https://www.mayoclinic.org/diseasesconditions/progeria/symptoms-causes/syc-20356038

10. Lamis A, Siddiqui SW, Ashok T, Patni N, Fatima M, Aneef AN. Hutchinson-Gilford Progeria Syndrome: A Literature Review. Cureus. 2022 Aug 31; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524302/

11. The Progeria Research Foundation. Progeria 101 FAQ | The Progeria Research Foundation [Internet]. The Progeria Research Foundation. 2024. Available from: https://www.progeriaresearch.org/progeria-101faq/

12. Progeria: a new kind of Laminopathy-- report of the First European Symposium on Progeria and creation of EURO-Progeria, a European Consortium on Progeria and related disorders. Brunet T, Bonne G, Denecke J, et al. https://pubmed.ncbi.nlm.nih.gov/16429102/ Podiatry Endocrinal Rev. 2004; 2: 39–45.

13. Gordon LB, Brown WT, Collins FS. Hutchinson-Gilford Progeria Syndrome. Seattle, WA: Gene Reviews; 1993. Hutchinson-Gilford Progeria Syndrome.

14. Kara N Shah, M. (2020, December 28. Hutchinson-Gilford Progeria Workup. 2020. https://emedicine.medscape.com/article/1117344-workup

15. Dhillon S. Lonafarnib: First Approval. Drugs. 2021 Feb; 81(2): 283-289. doi: 10.1007/s40265-020-01464-z. Erratum in: Drugs. 2021 Apr; 81(5):619. doi: 10.1007/s40265-021-01500-6. PMID: 33590450; PMCID: PMC7985116.

16. Hennekam RCM. Hutchinson–Gilford progeria syndrome: Review of the phenotype. American Journal of Medical Genetics Part A. 2006 Jul 12; 140A(23): 2603–2624. Available from: https://doi.org/10.1002/ajmg.a.31346

17. Shah KN. Hutchinson-Gilford Progeria: Practice Essentials, background, Pathophysiology. Available from: https://emedicine.medscape.com/article/1117344-overview?form=fpf#a1

18. Pereira S, Bourgeois P, Navarro C, Estevez-Vieira V, Chau P, De Sandre-Giovannoli A. HGPS and related premature aging disorders: from genomic identification to the first therapeutic approaches. Mech Ageing Dev. 2008; 129(7-8): 449-59.

19. DE chat T, Pfleghaar K, Sengupta K, et al. nuclear laminas: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 2008 Apr 1; 22(7):832-53.

20. Sickles CK, Gross GP. Progeria. StatPearls - NCBI Bookshelf. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507797/

21. Gang L, Liu Z, Zhang W, Li W, Wu Z, Wang W, Ren R, Su Y, Wang P, Sun L, Jiu Z, Chan P, Song M, Qu J, Liu GH. A chemical screen identifies a neuroprotective role of quercetin in premature aging. Protein Cell. 2019 Jun; 10(6): 417-435.

22. Oshawa J, Kato H, Tazawa Y, Yoke K. RECQ helicase disease and related progeria syndromes: RECQ2018 meeting. Mech Ageing Dev. 2018 Jul; 173: 80-83.

23. Sharma B, Sharma P, Joshi SC. Risk Factors, Prevalence and Diagnosis of Hutchison Gilford Syndrome with Special Reference To Case Reports. International Journal of Pharmacy and Pharmaceutical Sciences. 2017 May 1; 9(5): 1. Available from: https://doi.org/10.22159/ijpps.2017v9i5.16282

24. Progeria Research Foundation (PRF) webpage. Available from: http://www.progeriaresearch.org/meet_the_kids.html.

25. The Progeria Research Foundation. The Progeria Research Foundation - For the Children. For the Cure. The Progeria Research Foundation. 2024. Available from: http://www.progeriaresearch.org/progeria_101

26. Brown WT. Progeria: a human disease model of accelerated aging. Am J Clin Nutria. 1992; 55: 1222S–4S.

27. Gordon CM, Gordon LB, Snyder BD, Nazarene A, Quinn N, Huh S, et al. Hutchinson-Gilford progeria is a skeletal dysplasia. J Bone Miner Res. 2011 Jul. 26(7): 1670-9.

28. Ding SL, Shen CY. Model of human aging: recent findings on Werner's and Hutchinson-Gilford progeria syndromes. Clan Intern Aging. 2008. 3(3): 431-44.

29. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003 May 15; 423(6937): 293-8. doi: 10.1038/nature01629. Epub 2003 Apr 25. PMID: 12714972; PMCID: PMC10540076.

30. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, Lévy N. Lamin a truncation in Hutchinson-Gilford progeria. Science. 2003 Jun 27; 300(5628): 2055. doi: 10.1126/science.1084125. Epub 2003 Apr 17. PMID: 12702809.

31. Goldman RD, Gruenbaum Y, Moir RD, Shumaker DK, Spann TP. Nuclear lamins: building blocks of nuclear architecture. Genes Dev. 2002 Mar 1; 16(5): 533-47. doi: 10.1101/gad.960502. PMID: 11877373.

32. Gruenbaum Y, Margalit A, Goldman RD, Shumaker DK, Wilson KL. The nuclear lamina comes of age. Nat Rev Mol Cell Biol. 2005 Jan; 6(1): 21-31. doi: 10.1038/nrm1550. PMID: 15688064.

33. Dai Q, Choy E, Chiu V, Romano J, Slivka SR, Steitz SA, Michaelis S, Philips MR. Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum. J Biol Chem. 1998 Jun 12; 273(24): 15030-4. doi: 10.1074/jbc.273.24.15030. PMID: 9614111.

34. Mallampalli MP, Huyer G, Bendale P, Gelb MH, Michaelis S. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA. 2005 Oct 4; 102(40): 14416-21. doi: 10.1073/pnas.0503712102. Epub 2005 Sep 26. PMID: 16186497; PMCID: PMC1242289.

35. Glynn MW, Glover TW. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet. 2005 Oct 15; 14(20): 2959-69. doi: 10.1093/hmg/ddi326. Epub 2005 Aug 26. PMID: 16126733.

36. Röber RA, Weber K, Osborn M. Differential timing of nuclear lamin A/C expression in the various organs of the mouse embryo and the young animal: a developmental study. Development. 1989 Feb; 105(2): 365-78. doi: 10.1242/dev.105.2.365. PMID: 2680424.

37. Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, Gruenbaum Y, Khuon S, Mendez M, Varga R, Collins FS. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA. 2004 Jun 15; 101(24): 8963-8. doi: 10.1073/pnas.0402943101. Epub 2004 Jun 7. PMID: 15184648; PMCID: PMC428455.

38. Scaffidi P, Misteli T. Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med. 2005 Apr; 11(4): 440-5. doi: 10.1038/nm1204. Epub 2005 Mar 6. PMID: 15750600; PMCID: PMC1351119.

39. McClintock D, Gordon LB, Djabali K. Hutchinson-Gilford progeria mutant lamina A primarily targets human vascular cells as detected by an anti-Lamina a G608G antibody. Pros Natl Accad Sic USA. 2006 Feb 14. 103(7): 2154-9.

40. Olive M, Herten I, Mitchell R, Beers JK, Djabali K, Cao K, et al. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. ArteriosclerosisThrombiVacs Biol. 2010 Nov. 30(11): 2301-9.

41. Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Klein man ME, Miller DT, et al. Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. Hypertension. 2012 Jan. 59(1): 92-7.

42. Willaume S, Rass E, Fontanilla-Ramirez P, Moussa A, Wanschoor P, Bertrand P. A Link between Replicative Stress, Lamin Proteins, and Inflammation. Genes [Internet]. 2021 Apr 9; 12(4): 552. Available from: https://doi.org/10.3390/genes12040552

43. Progeria. Cleveland Clinic. 2024. Available from: https://my.clevelandclinic.org/health/diseases/17850-progeria

44. ABC Medical Center. Progeria: causes, symptoms, and treatment options | ABC Medical Center. ABC Medical Center. 2024. Available from: https://centromedicoabc.com/en/padecimientos/progeria/#signs-and-%20%20%20%20%20symptoms-progenitor

45. Progeria - Diagnosis and treatment - Mayo Clinic. 2023. Available from: https://www.mayoclinic.org/diseases-conditions/progeria/diagnosis-treatment/drc-20356043

46. Restage R, Chandler Mohan SM. Progeria syndrome: a case report. Indian J Orthoepy. 2008; 42: 97-9.

47. Henniker RCM. Hutchinson–Gilford progeria syndrome: a review of the phenotype. Is J Med Genet. 2006; 140: 2603-24

48. Meredith MA, Gordon LB, Claus’s S, Sachem V, Smith AC, Perry MB, et al. Phenotype and course of Hutchinson-Gilford progenies syndrome. N Engle J Med. 2008; 358: 592–604.

49. Gordon LB, McCartney KM, Giobbie-Hurder A. Disease progression in Hutchinson-Gilford progenies syndrome: impact on growth and development. Paediatrics. 2007; 120:824-33

50. Brown WT, Brower M, Kieran FJ. Progenies: a genetic disease model of premature aging. In: Harrison DE. Ed. Genetic Effects on Aging II; 1990. p. 521-42.

51. Gordon LB, Herten IA, Calibri A, Sukumaran G, Coca AB, Brown WT, et al. Hyaluronic is not elevated in urine or serum in Hutchinson-Gilford progenies syndrome. Hum Genet. 2003; 113: 178–87.

52. Gary MD, Sheen JC, Klamath-Loeb AS, Blank A, Sop her BL, Martin GM, et al. The Werner syndrome protein is DNA helices. Nat Genet. 1997; 17:100-3.

53. Gordon LB, Chappell H, Mossoro J, Agostino RB Sir, Brazier J, Campbell SE, et al. Association of Lonafarnib Treatment vs. No Treatment with Mortality Rate in Patients with Hutchinson-Gilford Progenies Syndrome. JAMA. 2018 Apr 24. 319 (16):1687-1695.

54. Rupa Bhattacharya, Samira R. Khan. Review on Progeria: A Rare Genetic Premature Aging Disorder. Res. J. Pharmacology and Pharmacodynamics. 2020; 12(2): 73-82.

55. Gayathri S. Effectiveness of Structured Teaching Programme on Care of Children with Genetic Disorders among III year B.Sc. Nursing students of RMCON, Chidambaram. Asian J. Nur. Edu. and Research 2016; 6(1): 79-80.

56. Kavitha D. Osteogenesis Imperfecta. Int. J. of Advances in Nur. Management. 2020; 8(4): 347-349.

57. Veerabhadrappa G Mendagudli. A Comprehensive Review of Down Syndrome: Molecular Basis, Clinical Characteristics and Therapeutic Prospects. International Journal of Advances in Nursing Management. 2024; 12(2): 99-0.

58. Bhawana. B. Bhende. Article on Tay-Sachs Disease. International Journal of Nursing Education and Research. 2021; 9(4): 475-8.

59. Bhagya Sree Lekha Annamneedi, Abhiram Sorra, Vinod Kumar Mugada, Srinivasa Rao Yarguntla. Wolfram Syndrome: A Rare Genetic disorder affecting Multiple Organ Systems. Research Journal of Pharmacology and Pharmacodynamics.2023; 15(4): 172-8.

60. Nigama Chandra Sattenapalli, Ranjit Prasad Swain, Siva Naga Koteswara Rao Gudhanti. Bridging between disorder, prevalence, clinical manifestation and therapeutic management of muscular dystrophy. Research Journal of Pharmacy and Technology. 2022; 15(11): 4901-7.

61. Sedigheh Iranmanesh, Ala Shamsi. The Relationship between Type of Cancer and Parent's Psychosocial Risks. Asian J. Nur. Edu. and Research. 2014; 4(4): 495-501.

62. Vinod V. Bagilkar, Bharatesh B. Savadatti. A descriptive study on Malnutrition. Asian J. Nur. Edu. and Research. 2015; 5(1): 72-77.

63. Proshob Mathew, Chandrashekar M. A Study to Assess the Emotional and Behavioral problems among Overweight Children in Selected Schools at Mysuru. Asian J. Nur. Edu. and Research. 2015; 5(4): 451-456

64. Anitha Rose Sunny, Anumol Varghese, Anusha Valsan, Benazeera, Asha P Shetty. Oral Health Status and Self reported Oral Hygienic Practices among School Children. Asian J. Nur. Edu. and Research. 2016; 6(3): 351-355.